-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse Börse FrankfurtEURSymbol SGT-
SeagenBörse Börse FrankfurtEURSymbol SGT
-
SeagenBörse Börse BerlinEURSymbol SGT
-
SEAGEN INCBörse Quotrix System der Börse DüsseldorfEURSymbol SGT
-
SEAGEN INCBörse Börse StuttgartEURSymbol SGT
-
SEAGEN INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol SGT
-
SEAGEN INCBörse Gettex System der Börse MünchenEURSymbol SGT
-
SeagenBörse NasdaqISIN US81181C1045 WKN: A2QFAQUSDSymbol SGEN
-
ISIN US8125781026 WKN: 602322USDSymbol SGEN
-
EURSymbol SGT
-
Seagen Inc.Börse London Stock Exchange
-
Symbol SGT
Währung
EUR
Börse
Börse Frankfurt Zeitzone: Europe/Berlin
Firmenname
Seagen Inc
Marktkapitalisierung
27.482.489.664 (+- 15%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
31.626.979.328 oder 23.338.000.000
Mitarbeiter
2.431 (+- 34%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
1.605 oder 3.256 Mitarbeiter
KGV
66.73
EBITDA 436.089.984
PEGRatio -0.08
Buchwert 12.889
Aktionärsstruktur der Seagen Inc
Portrait der Seagen Aktie
Das Unternehmen Seagen Inc aus USA beschäftigt 2.431 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie tätig.
Das Unternehmen Seagen Inc ist in mehr als 38 ETFs enthalten und somit eine vermutlich durchschnittlich bekannte Aktie. Der Spitzenreiter VanEck Vectors Biotech ETF gewichtet Seagen mit 4,44% im ETF.
Entdecke die 6 ETFs in denen Seagen Inc am höchsten gewichtet ist Insgesamt in 38 ETFs enthalten
Dir gefallen die Informationen zu Seagen?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Seagen?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Seagen?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Seagen?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
31 News & Informationen zur Seagen Aktie
Seagen Inc (SGEN): Price Now Near $160.19; Daily Chart Shows An Uptrend on 100 Day Basis
EDTX & NDTX Monthly Wrap-Up: July 2021
This month’s EDTX & NDTX Wrap-Up summarizes two decisions from the Eastern District of Texas that issued in late June and in July. In the first decision, Judge Schroeder addresses the…
Insights on the Targeted Therapeutics Global Market to 2031 – Featuring Sanofi, Takeda Pharmaceutical and Novartis Among Others
/PRNewswire/ — The “Targeted Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031” report has been added to…
Insights on the Targeted Therapeutics Global Market to 2031 – Featuring Sanofi, Takeda Pharmaceutical and Novartis Among Others
DUBLIN, July 30, 2021 /PRNewswire/ — The 'Targeted Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 202…
Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y
Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.
Seagen Inc. 2021 Q2 – Results – Earnings Call Presentation (NASDAQ:SGEN)
The following slide deck was published by Seagen Inc.
Seagen shares rise after Q2 earnings beat (NASDAQ:SGEN)
Seagen (SGEN) shares rise more than 2% post market after reporting second-quarter results that beat Wall Street estimates, helped by sales of its PADCEV and TUKYSA treatments.In…
EARNINGS SUMMARY: Details of Seagen Inc Q2 Earnings Report
(RTTNews) – Below are the earnings highlights for Seagen Inc (SGEN): -Earnings: -$84.58 million in Q2 vs. -$21.19 million in the same period last…
TELUS Corporation (TU): Are Hedge Funds Right About This Stock?
We at Insider Monkey have gone over 866 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the…
BeiGene Announces Approval In Canada Of BRUKINSA® (Zanubrutinib) For The Treatment Of Patients With Mantle Cell Lymphoma
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was s…
Garmin Ltd. (GRMN) Fell Out Of Favor With Hedge Funds
At Insider Monkey, we pore over the filings of nearly 866 top investment firms every quarter, a process we have now completed for the latest reporting…
Is Sirius XM Holdings Inc (SIRI) Going to Burn These Hedge Funds?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings…
Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate Phase 1 trials for…
Seagen (SGEN) Gets Regular Approval, Label Expansion for Padcev
Seagen and Astellas' two sBLAs for Padcev get FDA approval for patients with locally advanced or metastatic urothelial cancer. The approval comes one month before the PDUFA date of Aug 17, 2021.
Astellas Pharma : U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
– Regular Approval Based on Overall Survival Results from Confirmatory EV-301 Trial –
– First and Only FDA-Approved Therapy for Urothelial Cancer Patients Who Are Cisplatin-Ineligible and Have… | July 9, 2021
PADCEV (enfortumab Vedotin-ejfv) 20 Mg Vial US (Photo: Business Wire)
Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the U.S. Food and Drug
BeiGene : Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma
BeiGene, Ltd. , a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration has… | July 9, 2021
Seagen To Host Conference Call And Webcast Discussion Of Second Quarter 2021 Financial Results On July 29, 2021
Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2021 financial results on Thursday, July 29, 2021 after the close of U.S.
BeiGene Announces Acceptance Of A Supplemental Biologics License Application In China For Tislelizumab In Esophageal Squamous Cell Carcinoma (ESCC)
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today
New Biotechnology ETF Could Be a Stellar Second Half Idea
The Invesco Nasdaq Biotechnology ETF (IBBQ) is just a few weeks old, but even with that rookie status, it could be a stellar second half idea.
5 Stocks Growing Revenue Per Share Fast
GuruFocus Article or News written by Alberto Abaterusso and the topic is about: Their 5-year revenue per share growth rates have outperformed the S&P 500
Primecap Odyssey Funds' 2021 Semiannual Letter to Shareholders
GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Discussion of markets and holdings
Redmile Group, LLC Buys Jazz Pharmaceuticals PLC, Seagen Inc, Medtronic PLC, Sells AbbVie Inc, Gilead Sciences Inc, 1Life Healthcare Inc
GuruFocus Article or News written by insider and the topic is about:
Brooklyn ImmunoTherapeutics : EXECUTIVE EMPLOYMENT AGREEMENT (Form 8-K)
EXECUTIVE EMPLOYMENT AGREEMENT
BROOKLYN IMMUNOTHERAPEUTICS, INC
This EXECUTIVE EMPLOYMENT AGREEMENT dated as of June… | June 21, 2021
5 Blue-Chip Biotech Stocks to Buy in 2021
Discover the best biotech stocks to buy for both long-term investors and short-term traders as the industry continues to grow.
Addison Capital Co Buys Rent-A-Center Inc, Seagen Inc, International Flavors & Fragrances Inc, Sells Seagen Inc, DuPont de Nemours Inc, Blackrock Municipal Income Trust
Addison Capital Co Buys Rent-A-Center Inc, Seagen Inc, International Flavors & Fragrances Inc, Sells Seagen Inc, DuPont de Nemours Inc, Blackrock Municipal Income Trust, Stocks: RCII,SGEN,IFF,EPD,AMAT,SLYV,SGT,BFK,GOLD,BKH,, release date:Apr 12, 2021
Seagen: The New Oncology Hope (NASDAQ:SGEN)
In recent years, Seagen has undergone a transformation from a one-product company to a diversified player in the oncology drug market.
Seagen is seen heading towards a ‘catalyst-rich 2021’ – BofA (NASDAQ:SGEN)
The Top 3 Biotech Stocks to Buy in 2021
Revenue growth is just beginning for these companies.
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Media Release COPENHAGEN, Denmark, Jan. 04, 2021 Initiation of a global phase 3 trial for tisotumab vedotin versus investigator’s choice chemotherapy in …